Association between obstructive sleep apnea severity and glucose control in patients with untreated versus treated diabetes

<jats:title>Summary</jats:title><jats:p>The purpose of this study was to determine whether the association between obstructive sleep apnea severity and glucose control differs between patients with newly diagnosed and untreated type 2 diabetes, and patients with known and treated type 2 diabetes. This multicentre cross‐sectional study included 762 patients investigated by sleep recording for suspected obstructive sleep apnea, 497 of whom were previously diagnosed and treated for type 2 diabetes (treated diabetic patients), while 265 had no medical history of diabetes but had fasting blood glucose ≥126 mg dL<jats:sup>−1</jats:sup> and/or glycated haemoglobin (HbA<jats:sub>1c</jats:sub>) ≥6.5% consistent with newly diagnosed type 2 diabetes (untreated diabetic patients). Multivariate regression analyses were performed to evaluate the independent association between HbA<jats:sub>1c</jats:sub> and obstructive sleep apnea severity in treated and untreated patients with diabetes. In untreated diabetic patients, HbA<jats:sub>1c</jats:sub> was positively associated with apnea–hypopnea index (<jats:italic>P </jats:italic>=<jats:italic> </jats:italic>0.0007) and 3% oxygen desaturation index (<jats:italic>P </jats:italic>=<jats:italic> </jats:italic>0.0016) after adjustment for age, gender, body mass index, alcohol habits, metabolic dyslipidaemia, hypertension, statin use and study site. The adjusted mean value of HbA<jats:sub>1c</jats:sub> increased from 6.68% in the lowest quartile of the apnea–hypopnea index (<17) to 7.20% in the highest quartile of the apnea–hypopnea index (>61; <jats:italic>P </jats:italic>=<jats:italic> </jats:italic>0.033 for linear trend). In treated patients with diabetes, HbA<jats:sub>1c</jats:sub> was associated with non‐sleep variables, including age, metabolic dyslipidaemia and insulin use, but not with obstructive sleep apnea severity. Obstructive sleep apnea may adversely affect glucose control in patients with newly diagnosed and untreated type 2 diabetes, but may have a limited impact in patients with overt type 2 diabetes receiving anti‐diabetic medications.</jats:p>